Swiss MedTech Firm Ypsomed Opens First Facility in US

Swiss medical technology company Ypsomed on Friday announced that it will establish its first manufacturing facility at Holly Springs in Wake County, North Carolina in the US, by investing around $248 million in a first phase.

This is another milestone in Ypsomed’s global growth strategy, bringing the company closer to its customers and enabling it to serve local markets directly. From end of 2027 onwards, the new site in Holly Springs will supply products for the US market.

The North American manufacturing facility will expand Ypsomed’s production capacity and strengthen its global partnerships. To accelerate its expansion, Ypsomed which is the maker of self-injection systems, buying a building with 15,000 sq. m. with an option for further expansion.

The company initially plans to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases, it said in an official release.

Ypsomed CEO Simon Michel said that establishing their new production site in the US marks an important step in his company’s global growth strategy. Holly Springs, a location at the heart of their industry, close to the customers was deliberately chosen.

“The cooperative approach of the local authorities, the excellent infrastructure, and the proximity to top-tier universities provide ideal conditions for our future growth. This environment will allow us to attract the skilled workforce we need and to further strengthen our position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the U.S. healthcare market,” Simon added.

A Growth Hub

Holly Springs Mayor Sean Mayefskie said that with more than 650 life sciences operations in North Carolina’s Research Triangle alone, every stage of the biopharmaceutical supply chain is represented from research and product development to device manufacturing, fill/finish, and delivery.

“Wake County brings together research, talent and community to scale the industry and move ideas to market. This announcement brings an expansion in the life science offerings in Holly Springs, diversifying the types of companies located here,” he explained.

He also said that everyone knows about the global biotech leaders who call Holly Springs home, and Ypsomed will provide needed supplies to contribute to the creation of life-saving medications these companies will produce right here in Holly Springs.

Global Growth Strategy

Ypsomed is consistently driving forward its global growth strategy to meet the worldwide increase in demand for injection systems for self-medication and to further strengthen customer proximity. This year, the company opened its first own manufacturing site in Changzhou, China, and launched the expansion of its “Schwerin 2” production facility in Germany.

Over the coming years, Ypsomed will invest millions of dollars in state-of-the-art infrastructure at this site. Ypsomed is also investing in expanding its production capacities in Switzerland.

After modernising and enlarging its Lochbach production site in Burgdorf in 2023, the company is now taking the next step: around $248 million are being invested in the expansion of the Solothurn site. The corresponding construction and renovation work has already begun, Ypsomed said.